Full metadata record
DC FieldValueLanguage
dc.contributor.authorTatokoro, Manabu-
dc.contributor.authorKoga, Fumitaka-
dc.contributor.authorYoshida, Soichiro-
dc.contributor.authorKihara, Kazunori-
dc.date.accessioned2015-04-22T12:36:11Z-
dc.date.available2015-04-22T12:36:11Z-
dc.date.issued2015-01-06-
dc.identifier.issn1611-2156-
dc.identifier.urihttp://hdl.handle.net/2003/34053-
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-7601-
dc.description.abstractHeat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone that plays a role in stabilizing and activating more than 200 client proteins. It is required for the stability and function of numerous oncogenic signaling proteins that determine the hallmarks of cancer. Since the initial discovery of the first Hsp90 inhibitor in the 1970s, multiple phase II and III clinical trials of several Hsp90 inhibitors have been undertaken. This review provides an overview of the current status on clinical trials of Hsp90 inhibitors and future perspectives on novel anticancer strategies using Hsp90 inhibitors.en
dc.language.isoen-
dc.relation.ispartofseriesEXCLI Journal ; Vol. 14, 2015en
dc.subjectHsp90 inhibitoren
dc.subjectcanceren
dc.subjectclinical trialen
dc.subjectbladder canceren
dc.subject.ddc610-
dc.titleHeat shock protein 90 targeting therapyen
dc.title.alternativestate of the art and future perspectiveen
dc.typeText-
dc.type.publicationtypearticle-
dcterms.accessRightsopen access-
eldorado.dnb.zdberstkatid2132560-1-
Appears in Collections:Review Articles

Files in This Item:
File Description SizeFormat 
Koga_06012015_proof.pdfDNB119.52 kBAdobe PDFView/Open


This item is protected by original copyright



This item is protected by original copyright rightsstatements.org